Literature DB >> 15337722

Bacterial vaginosis: more questions than answers.

Erica Weir1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15337722      PMCID： PMC514637          DOI： 10.1503/cmaj.1041174

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  3 in total

Review 1.  Preventing adverse sequelae of bacterial vaginosis: a public health program and research agenda.

Authors:  E H Koumans; J S Kendrick
Journal:  Sex Transm Dis       Date:  2001-05       Impact factor: 2.830

Review 2.  Antibiotics for treating bacterial vaginosis in pregnancy.

Authors:  H McDonald; P Brocklehurst; J Parsons; R Vigneswaran
Journal:  Cochrane Database Syst Rev       Date:  2003

Review 3.  Gynecologic conditions and bacterial vaginosis: implications for the non-pregnant patient.

Authors:  R L Sweet
Journal:  Infect Dis Obstet Gynecol       Date:  2000
  3 in total
  5 in total

1.  Elucidation of the Molecular Mechanisms of Action of the Natural Antimicrobial Peptide Subtilosin Against the Bacterial Vaginosis-associated Pathogen Gardnerella vaginalis.

Authors:  Katia Sutyak Noll; Patrick J Sinko; Michael L Chikindas
Journal:  Probiotics Antimicrob Proteins       Date:  2011-03       Impact factor: 4.609

2.  Lactocin 160, a Bacteriocin Produced by Vaginal Lactobacillus rhamnosus, Targets Cytoplasmic Membranes of the Vaginal Pathogen, Gardnerella vaginalis.

Authors:  Yevgeniy Turovskiy; Richard D Ludescher; Alla A Aroutcheva; Sebastian Faro; Michael L Chikindas
Journal:  Probiotics Antimicrob Proteins       Date:  2009-01-20       Impact factor: 4.609

3.  The vaginal microbiome in health and disease.

Authors:  Bryan A White; Douglas J Creedon; Karen E Nelson; Brenda A Wilson
Journal:  Trends Endocrinol Metab       Date:  2011-07-13       Impact factor: 12.015

4.  The natural antimicrobial peptide subtilosin acts synergistically with glycerol monolaurate, lauric arginate, and ε-poly-L-lysine against bacterial vaginosis-associated pathogens but not human lactobacilli.

Authors:  Katia Sutyak Noll; Mark N Prichard; Arkady Khaykin; Patrick J Sinko; Michael L Chikindas
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

5.  Preclinical Evaluation of Tolerability of a Selective, Bacteriostatic, Locally Active Vaginal Formulation.

Authors:  Luca Ivan Ardolino; Marisa Meloni; Giuseppe Brugali; Emanuela Corsini; Corrado Lodovico Galli
Journal:  Curr Ther Res Clin Exp       Date:  2016-07-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.